Yuanyuan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuanyuan Zhang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Liudi Chang
School of Clinical Medicine, Shandong Second Medical University, Weifang, China
3 shared publicationsShuhui Zhuang
Department of Hematology, Linyi People’s Hospital, Linyi, Shandong, China
3 shared publications- Lanlan Zang
Department of Pharmacy, Linyi People's Hospital Shandong Second Medical University Linyi Shandong China
2 shared publications Weiwen Hu
Department of Hematology, Linyi People’s Hospital, Linyi, Shandong, China
2 shared publicationsXiaoxi Feng
Department of Hematology, Linyi People’s Hospital, Linyi, Shandong, China
2 shared publicationsZhaobo Yang
Spine surgery, Linyi People’s Hospital, Shandong Second Medical University, Linyi, Shandong, China
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Springer Nature in Discover Oncology
Epigenetic mechanisms in breast cancer: pathogenesis, therapeutic targets, and clinical implications
- 3 September 2026
- Published by Springer Nature in Discover Oncology
Open AccessEpigenetic mechanisms in breast cancer: pathogenesis, therapeutic targets, and clinical implications
- Open Access
- 26 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1724247
Fluid overload-associated large B-cell lymphoma: two case report and review of literature
Background: Fluid overload-associated large B-cell lymphoma (FO-LBCL) is an exceptionally rare lymphoma characterized by predominant involvement of serous body cavities—such as the pleura, peritoneum, and pericardium—in the absence of a solid tumor mass. Its low incidence and nonspecific clinical presentation, which often includes symptoms like dyspnea due to effusion, contribute to diagnostic challenges in early stages. This study aims to address current gaps in the understanding of FO-LBCL by reporting two new cases and reviewing the clinical features, treatment regimens, and outcomes of 57 documented patients. Furthermore, through a detailed analysis of FO-LBCL characteristics, this work discusses relevant differential diagnoses and potential treatment strategies. Methods: A literature search of PubMed and Web of Science was performed using the following search queries: (1) “Fluid overload-associated large B-cell lymphoma” OR “FO-LBC”; (2) “Human herpesvirus 8-unrelated” AND “effusion lymphoma”; (3) “HHV8-unrelated” AND “effusion lymphoma”. Results: This study included a total of 57 patients. Fluid accumulation most commonly affected the pleural cavity (84.2%), followed by the pericardial (31.6%) and peritoneal (21.1%) cavities. The predominant clinical manifestation was dyspnea (55.8%). Chemotherapy was the primary treatment modality (56.1%), with the R-CHOP regimen representing the most commonly administered protocol. CD20 expression was the most significant favorable prognostic factor (P = 6×10-7). Other factors associated with improved survival included the absence of CD138 expression (P = 0.0009), age ≥ 65 years (P = 0.0015), LDH ≤ 500 U/L (P = 0.0064), the presence of pleural effusion (P = 0.0099), and CD79a expression (P = 0.0411). Treatment with rituximabcontaining chemotherapy regimens was also a significant favorable factor (P = 0.0036). Conclusions: FO-LBCL often presents with dyspnea caused by fluid effusion. Routine laboratory tests typically show no significant abnormalities, making timely pathological examination essential for a definitive diagnosis. Clinicians should enhance their understanding of FO-LBCL characteristics to improve early diagnostic accuracy. It is crucial to select appropriate treatment strategies based on prognostic factors.
- 26 November 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1724247
Open AccessFluid overload-associated large B-cell lymphoma: two case report and review of literature
Background: Fluid overload-associated large B-cell lymphoma (FO-LBCL) is an exceptionally rare lymphoma characterized by predominant involvement of serous body cavities—such as the pleura, peritoneum, and pericardium—in the absence of a solid tumor mass. Its low incidence and nonspecific clinical presentation, which often includes symptoms like dyspnea due to effusion, contribute to diagnostic challenges in early stages. This study aims to address current gaps in the understanding of FO-LBCL by reporting two new cases and reviewing the clinical features, treatment regimens, and outcomes of 57 documented patients. Furthermore, through a detailed analysis of FO-LBCL characteristics, this work discusses relevant differential diagnoses and potential treatment strategies. Methods: A literature search of PubMed and Web of Science was performed using the following search queries: (1) “Fluid overload-associated large B-cell lymphoma” OR “FO-LBC”; (2) “Human herpesvirus 8-unrelated” AND “effusion lymphoma”; (3) “HHV8-unrelated” AND “effusion lymphoma”. Results: This study included a total of 57 patients. Fluid accumulation most commonly affected the pleural cavity (84.2%), followed by the pericardial (31.6%) and peritoneal (21.1%) cavities. The predominant clinical manifestation was dyspnea (55.8%). Chemotherapy was the primary treatment modality (56.1%), with the R-CHOP regimen representing the most commonly administered protocol. CD20 expression was the most significant favorable prognostic factor (P = 6×10-7). Other factors associated with improved survival included the absence of CD138 expression (P = 0.0009), age ≥ 65 years (P = 0.0015), LDH ≤ 500 U/L (P = 0.0064), the presence of pleural effusion (P = 0.0099), and CD79a expression (P = 0.0411). Treatment with rituximabcontaining chemotherapy regimens was also a significant favorable factor (P = 0.0036). Conclusions: FO-LBCL often presents with dyspnea caused by fluid effusion. Routine laboratory tests typically show no significant abnormalities, making timely pathological examination essential for a definitive diagnosis. Clinicians should enhance their understanding of FO-LBCL characteristics to improve early diagnostic accuracy. It is crucial to select appropriate treatment strategies based on prognostic factors.
- Open Access
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1509100
Primary cardiac lymphoma: a clinicopathological study of 121 cases
Background: Primary cardiac lymphoma (PCL) is an exceedingly uncommon type of lymphoma that primarily affects the heart and/or pericardium, or manifests through cardiac symptoms due to myocardial infiltration. The infrequency of PCL, coupled with its non-specific clinical presentations, often complicates early diagnosis. This study aims to fill the existing gap in clinical knowledge regarding PCL by detailing a case of PCL and examining its clinical features, auxiliary examinations, treatment approaches, and prognostic outcomes, thereby facilitating early detection and enhancing patient care.Methods: A thorough search of the PubMed and Chinese National Knowledge Infrastructure (CNKI) database was performed using keywords “heart” and “lymphoma” or “primary cardiac lymphoma”. This search encompassed publications from January 1, 2014, to November 1, 2024.Results: The review included 121 cases. These cases usually present with atypical symptoms, mainly circulatory and respiratory, including chest tightness, dyspnea, and edema, along with occasional neurological and gastrointestinal symptoms. Echocardiography served as the primary diagnostic method in 92.6% of cases, while a definitive diagnosis was achieved through pathological examination in all cases (100%). Treatment strategies predominantly included surgical intervention (44.6%) and chemotherapy (76.0%). Although surgery did not have a significant effect on survival rates, chemotherapy proved to be critical in improving patient survival.Conclusions: PCL, which arises in the cardiac or pericardial areas, is generally associated with a poor prognosis. It is essential for clinicians to develop a greater awareness and understanding of the characteristics of PCL to enhance early diagnosis. The timely initiation of chemotherapy is vital for improving survival rates and the overall quality of life for patients with PCL.
- 7 January 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1509100
Open AccessPrimary cardiac lymphoma: a clinicopathological study of 121 cases
Background: Primary cardiac lymphoma (PCL) is an exceedingly uncommon type of lymphoma that primarily affects the heart and/or pericardium, or manifests through cardiac symptoms due to myocardial infiltration. The infrequency of PCL, coupled with its non-specific clinical presentations, often complicates early diagnosis. This study aims to fill the existing gap in clinical knowledge regarding PCL by detailing a case of PCL and examining its clinical features, auxiliary examinations, treatment approaches, and prognostic outcomes, thereby facilitating early detection and enhancing patient care.Methods: A thorough search of the PubMed and Chinese National Knowledge Infrastructure (CNKI) database was performed using keywords “heart” and “lymphoma” or “primary cardiac lymphoma”. This search encompassed publications from January 1, 2014, to November 1, 2024.Results: The review included 121 cases. These cases usually present with atypical symptoms, mainly circulatory and respiratory, including chest tightness, dyspnea, and edema, along with occasional neurological and gastrointestinal symptoms. Echocardiography served as the primary diagnostic method in 92.6% of cases, while a definitive diagnosis was achieved through pathological examination in all cases (100%). Treatment strategies predominantly included surgical intervention (44.6%) and chemotherapy (76.0%). Although surgery did not have a significant effect on survival rates, chemotherapy proved to be critical in improving patient survival.Conclusions: PCL, which arises in the cardiac or pericardial areas, is generally associated with a poor prognosis. It is essential for clinicians to develop a greater awareness and understanding of the characteristics of PCL to enhance early diagnosis. The timely initiation of chemotherapy is vital for improving survival rates and the overall quality of life for patients with PCL.
- 9 December 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5085-5101
Advances in epigenetic therapies for B-cell non-hodgkin lymphoma
B-cell non-Hodgkin lymphomas (B-NHLs) constitute a varied group of cancers originating from B lymphocytes. B-NHLs can occur at any stage of normal B-cell development, with most arising from germinal centres (e.g. diffuse large B-cell lymphoma, DLBCL and follicular lymphoma, FL). The standard initial treatment usually involves the chemoimmunotherapy regimen. Although there is a high initial response rate, 30–40% of high-risk patients often face relapsed or refractory lymphoma due to drug resistance. Recent research has uncovered a significant link between the development of B-NHLs and various epigenetic processes, such as DNA methylation, histone modification, regulation by non-coding RNAs, and chromatin remodeling. Therapies targeting these epigenetic changes have demonstrated considerable potential in clinical studies. This article examines the influence of epigenetic regulation on the onset and progression of B-NHLs. It discusses the current therapeutic targets and agents linked to these epigenetic mechanisms, with the goal of offering new perspectives and approaches for targeted therapies and combination chemotherapy in treating B-NHLs.
- 9 December 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (12) , 5085-5101
Advances in epigenetic therapies for B-cell non-hodgkin lymphoma
B-cell non-Hodgkin lymphomas (B-NHLs) constitute a varied group of cancers originating from B lymphocytes. B-NHLs can occur at any stage of normal B-cell development, with most arising from germinal centres (e.g. diffuse large B-cell lymphoma, DLBCL and follicular lymphoma, FL). The standard initial treatment usually involves the chemoimmunotherapy regimen. Although there is a high initial response rate, 30–40% of high-risk patients often face relapsed or refractory lymphoma due to drug resistance. Recent research has uncovered a significant link between the development of B-NHLs and various epigenetic processes, such as DNA methylation, histone modification, regulation by non-coding RNAs, and chromatin remodeling. Therapies targeting these epigenetic changes have demonstrated considerable potential in clinical studies. This article examines the influence of epigenetic regulation on the onset and progression of B-NHLs. It discusses the current therapeutic targets and agents linked to these epigenetic mechanisms, with the goal of offering new perspectives and approaches for targeted therapies and combination chemotherapy in treating B-NHLs.
- 15 August 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (5) , 1435-1454
Epigenetic alterations and advancement of lymphoma treatment
Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone modifications, non-coding RNA regulation, and RNA modifications play crucial roles in lymphoma pathogenesis. Epigenetic modification–targeting drugs have exhibited therapeutic efficacy and tolerability in both monotherapy and combination lymphoma therapy. This review discusses pathogenic mechanisms and potential epigenetic therapeutic targets in common lymphomas, offering new avenues for lymphoma diagnosis and treatment. We also discuss the shortcomings of current lymphoma treatments, while suggesting potential areas for future research, in order to improve the prediction and prognosis of lymphoma.
- 15 August 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (5) , 1435-1454
Epigenetic alterations and advancement of lymphoma treatment
Lymphomas, complex and heterogeneous malignant tumors, originate from the lymphopoietic system. These tumors are notorious for their high recurrence rates and resistance to treatment, which leads to poor prognoses. As ongoing research has shown, epigenetic modifications like DNA methylation, histone modifications, non-coding RNA regulation, and RNA modifications play crucial roles in lymphoma pathogenesis. Epigenetic modification–targeting drugs have exhibited therapeutic efficacy and tolerability in both monotherapy and combination lymphoma therapy. This review discusses pathogenic mechanisms and potential epigenetic therapeutic targets in common lymphomas, offering new avenues for lymphoma diagnosis and treatment. We also discuss the shortcomings of current lymphoma treatments, while suggesting potential areas for future research, in order to improve the prediction and prognosis of lymphoma.